ZBIO (Zenas BioPharma) Institutional Ownership: 87.82% (As of Aug. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ZBIO Zenas BioPharma Inc ZBIO
8 GF Score
Price $33.17
! 4 Warning Signs
View Full Analysis

What is Zenas BioPharma Institutional Ownership?

Zenas BioPharma ZBIO +0.39% 8 Institutional Ownership is 87.82% as of Aug. 27, 2026. GuruFocus rates ZBIO with a GF Score™ of 8/100. The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Zenas BioPharma's institutional ownership is 87.82%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Zenas BioPharma's Insider Ownership is 0.75%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Zenas BioPharma's Float Percentage Of Total Shares Outstanding is 68.11%.

Zenas BioPharma Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Zenas BioPharma's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zenas BioPharma Institutional Ownership Chart

Zenas BioPharma Historical Data

The historical data trend for Zenas BioPharma can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 31.81 33.61 36.45 36.74 38.21 51.46 53.40 53.60 51.80 50.43
ZBIO
8GF Score
Zenas BioPharma Inc ZBIO
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zenas BioPharma Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 87.82% mean?
Zenas BioPharma (ZBIO) has a Institutional Ownership of 87.82% as of Aug. 27, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Zenas BioPharma and its competitors.
Is Zenas BioPharma's Institutional Ownership too high?
Zenas BioPharma's current Institutional Ownership is 87.82%. Overall, Zenas BioPharma has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Zenas BioPharma's Institutional Ownership compare to ADMA and PGEN?
Zenas BioPharma's Institutional Ownership of 87.82% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Zenas BioPharma and its competitors. Zenas BioPharma's current Institutional Ownership is 87.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenas BioPharma stock overvalued right now?
Zenas BioPharma (ZBIO) has a current Institutional Ownership of 87.82%. The current Institutional Ownership is 87.82%. Zenas BioPharma's overall GF Score™ is 8/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Zenas BioPharma (ZBIO), the current Institutional Ownership is 87.82% as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zenas BioPharma Business Description

Address 852 Winter Street, Suite 250, Waltham, MA, USA, 02451
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
8GF Score

Get the complete analysis for ZBIO

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$33.17
Price